Trial · NCT05245071
Adverse events29
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 29
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Decreased Appetite | Metabolism and nutrition disorders | Tusamitamab Ravtansine 100 mg/m^2 | 9 | 22 | 10 |
| other | Keratitis | Eye disorders | Tusamitamab Ravtansine 100 mg/m^2 | 3 | 22 | 6 |
| other | Keratopathy | Eye disorders | Tusamitamab Ravtansine 100 mg/m^2 | 3 | 22 | 3 |
| other | Hypertension | Vascular disorders | Tusamitamab Ravtansine 100 mg/m^2 | 3 | 22 | 3 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Tusamitamab Ravtansine 100 mg/m^2 | 3 | 22 | 3 |
| other | Nasal Congestion | Respiratory, thoracic and mediastinal disorders | Tusamitamab Ravtansine 100 mg/m^2 | 2 | 22 | 2 |
| other | Constipation | Gastrointestinal disorders | Tusamitamab Ravtansine 100 mg/m^2 | 3 | 22 | 3 |
| other | Nausea | Gastrointestinal disorders | Tusamitamab Ravtansine 100 mg/m^2 | 6 | 22 | 7 |
| other | Stomatitis | Gastrointestinal disorders | Tusamitamab Ravtansine 100 mg/m^2 | 2 | 22 | 2 |
| other | Vomiting | Gastrointestinal disorders | Tusamitamab Ravtansine 100 mg/m^2 | 2 | 22 | 3 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Tusamitamab Ravtansine 100 mg/m^2 | 3 | 22 | 3 |
| other | Back Pain | Musculoskeletal and connective tissue disorders | Tusamitamab Ravtansine 100 mg/m^2 | 3 | 22 | 3 |
| other | Renal Failure | Renal and urinary disorders | Tusamitamab Ravtansine 100 mg/m^2 | 2 | 22 | 2 |
| other | Asthenia | General disorders | Tusamitamab Ravtansine 100 mg/m^2 | 6 | 22 | 7 |
| other | Fatigue | General disorders | Tusamitamab Ravtansine 100 mg/m^2 | 3 | 22 | 3 |
| other | Non-Cardiac Chest Pain | General disorders | Tusamitamab Ravtansine 100 mg/m^2 | 3 | 22 | 3 |
| other | Oedema Peripheral | General disorders | Tusamitamab Ravtansine 100 mg/m^2 | 2 | 22 | 2 |
| other | Pyrexia | General disorders | Tusamitamab Ravtansine 100 mg/m^2 | 2 | 22 | 2 |
| other | Weight Decreased | Investigations | Tusamitamab Ravtansine 100 mg/m^2 | 3 | 22 | 3 |
| serious | Pneumonia | Infections and infestations | Tusamitamab Ravtansine 100 mg/m^2 | 2 | 22 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05245071/events